🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11911464

Anti-parasitic immunological compositions

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11903936

Anti-malarial agents

The Board of Regents of the University of Texas System · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897933

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897945

Methods of treating allergy using anti-Bet v 1 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11890353

Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based t

Northwestern University · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884657

PI-kinase inhibitors with anti-infective activity

The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11883433

Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof

CELLENGENE INC. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884740

Anti-CD20 antibody compositions

TG Therapeutics, Inc. · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11879017

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of sa

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866502

Anti-FGFR2 antibodies and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866488

Compositions comprising an anti-metallothionein antibody and a pancreatic cell targeting m

UNIVERSITY OF CONNECTICUT · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11859007

Humanized anti-CD73 antibodies

Corvus Pharmaceuticals, Inc. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11859000

Anti-CCR8 antibodies and uses thereof

VACCINEX, INC. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11857701

Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applicati

The Board of Regents of the University of Texas System · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851422

Anti-viral compounds

Aligos Therapeutics, Inc. · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851498

Anti-CD276 antibodies (B7H3)

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11840561

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839660

Anti-transferrin receptor antibody and uses thereof

Dyne Therapeutics, Inc. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839642

Anti-angiogenin peptides, compositions, and methods of use

The Board of Regents of the University of Oklahoma · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11834512

Inhibiting anti-ENPP1 antibodies

The Regents of the University of California · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11834507

Anti-MET agonist antibody for use in the treatment of colorectal cancer

AGOMAB THERAPEUTICS · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11827683

Bi-functional anti-tau polypeptides and use thereof

REGENERATIVE RESEARCH FOUNDATION · Granted Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11820826

Anti-NPR1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11814439

Anti-CD20 antibody compositions

TG Therapeutics, Inc. · Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted